Please assess the completion status of the following clinical trial:

Trial Title: A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose~* Males and Females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age~* HbA1c must be ≥7.5% and ≤10% at screening~* Fasting Plasma Glucose must be \<240 mg/dL at screening~Exclusion Criteria:~* History of type 1 diabetes~* History of diabetic ketoacidosis~* NYHA Class III or IV cardiac status or hospitalization for congestive heart failure within 6 weeks prior to Visit 1~* Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening~* Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 month prior to screening~* Body mass index \>45 kg/m2~* Fasting triglycerides \>500 mg/dL~* Uncontrolled hypertension (sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>100 mmHg~* Presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INT131 besylate 0.5 mg (Type: EXPERIMENTAL): INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
- INT131 besylate 1 mg (Type: EXPERIMENTAL): INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
- INT131 besylate 2 mg (Type: EXPERIMENTAL): INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
- INT131 besylate 3 mg (Type: EXPERIMENTAL): INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
- pioglitazone HCl 45 mg (Type: ACTIVE_COMPARATOR): pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
- placebo (Type: PLACEBO_COMPARATOR): placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).